161 related articles for article (PubMed ID: 31900603)
1. Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes.
Williams JH; Udata C; Ganguly BJ; Bucktrout SL; Joh T; Shannon M; Wong GY; Levisetti M; Garzone PD; Meng X
AAPS J; 2020 Jan; 22(2):23. PubMed ID: 31900603
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
Timmermann S; Hall A
Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes.
Herold KC; Bucktrout SL; Wang X; Bode BW; Gitelman SE; Gottlieb PA; Hughes J; Joh T; McGill JB; Pettus JH; Potluri S; Schatz D; Shannon M; Udata C; Wong G; Levisetti M; Ganguly BJ; Garzone PD;
JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31852846
[TBL] [Abstract][Full Text] [Related]
4. Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
Vlasakakis G; Napolitano A; Barnard R; Brown K; Bullman J; Inman D; Keymeulen B; Lanham D; Leirens Q; MacDonald A; Mezzalana E; Page K; Patel M; Savage CO; Zamuner S; van Maurik A
Br J Clin Pharmacol; 2019 Apr; 85(4):704-714. PubMed ID: 30566758
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.
Bihorel S; Fiedler-Kelly J; Ludwig E; Sloan-Lancaster J; Raddad E
AAPS J; 2014 Sep; 16(5):1009-17. PubMed ID: 24912797
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
Li C; Shoji S; Beebe J
Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
8. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
Dong JQ; Rossulek M; Somayaji VR; Baltrukonis D; Liang Y; Hudson K; Hernandez-Illas M; Calle RA
Br J Clin Pharmacol; 2015 Nov; 80(5):1051-63. PubMed ID: 25940675
[TBL] [Abstract][Full Text] [Related]
10. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Minocha M; Tran JQ; Sheridan JP; Othman AA
Clin Pharmacokinet; 2016 Jan; 55(1):121-30. PubMed ID: 26242380
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
Li Z; Radin A; Li M; Hamilton JD; Kajiwara M; Davis JD; Takahashi Y; Hasegawa S; Ming JE; DiCioccio AT; Li Y; Kovalenko P; Lu Q; Ortemann-Renon C; Ardeleanu M; Swanson BN
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):742-755. PubMed ID: 32348036
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
[TBL] [Abstract][Full Text] [Related]
14. IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Long SA; Buckner JH; Greenbaum CJ
Clin Immunol; 2013 Dec; 149(3):324-31. PubMed ID: 23499139
[TBL] [Abstract][Full Text] [Related]
15. Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function.
Lee LF; Logronio K; Tu GH; Zhai W; Ni I; Mei L; Dilley J; Yu J; Rajpal A; Brown C; Appah C; Chin SM; Han B; Affolter T; Lin JC
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12674-9. PubMed ID: 22733769
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
17. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA; Pekalski ML; Kareclas P; Evangelou M; Walker NM; Howlett J; Mander AP; Kennet J; Wicker LS; Bond S; Todd JA; Waldron-Lynch F
BMJ Open; 2015 Dec; 5(12):e009799. PubMed ID: 26646829
[TBL] [Abstract][Full Text] [Related]
18. CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.
Brenu EW; Bartley TJ; Wright CM; Hamilton-Williams EE
Immunol Cell Biol; 2017 Oct; 95(9):803-813. PubMed ID: 28611472
[TBL] [Abstract][Full Text] [Related]
19. Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice.
Koprivica I; Vujičić M; Gajić D; Saksida T; Stojanović I
Front Immunol; 2018; 9():3130. PubMed ID: 30687329
[TBL] [Abstract][Full Text] [Related]
20. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody.
Vignali D; Gürth CM; Pellegrini S; Sordi V; Sizzano F; Piemonti L; Monti P
Transplantation; 2016 Sep; 100(9):1853-61. PubMed ID: 27306531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
